[Pe-09] 一般演題ポスターセッション（英語）09 神経免疫 02

[Pe-09-7] Eculizumab efficacy and safety in NMOSD patients treated with prior rituximab: findings from PREVENT

^○藤原 一男^1,2, Michael Levy³, Achim Berthele⁴, Ho Jin Kim⁵, 中島 一郎⁶, Celia Oreja-Guevara⁷, Jacqueline Palace⁸, Sean J Pittock⁹, Murat Terzi¹⁰, Dean M Wingerchuk⁹ (1.脳神経疾患研究所 多発性硬化症・視神経脊髄炎センター, 2.福島県立医科大学, 3.Massachusetts General Hospital and Harvard Medical School, 4.Technical University of Munich, 5.Research Institute and Hospital, Goyang, 6.東北医科薬科大学, 7.Hospital Universitario Clinico San Carlos, 8.John Radcliffe Hospita, 9.Mayo Clinic, 10.Ondokuz Mayıs University)

Kazuo Fujihara, M.D.is Professor, Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, and Director, Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan. He is currently serving as President (2018~) of Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), and President (2019~) of Japanese Society for Neuroimmunology (JSNI).